NFL Biosciences SAS
Research NFL Biosciences SAS (ALNFL) on Bullrun: market cap EUR 10.64M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALNFL
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 10.64M
- Financial periodFY2025
- Net income-EUR 3.32M
Valuation Snapshot
latest market cap is EUR 10.64M.
About NFL Biosciences SAS
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation.
Frequently asked questions
What is NFL Biosciences SAS's market cap?
NFL Biosciences SAS's market capitalization is EUR 10.64M.
What does NFL Biosciences SAS do?
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials;